Bcr‐Abl activates AURKA and AURKB in chronic myeloid leukemia cells <i>via</i> AKT signaling
Jing Yang(Xuzhou Medical College), Akihito Yokoyama(Kōchi University)
Cited by 39
Related Papers
Downregulation of miR‐217 correlates with resistance of ph<sup>+</sup> leukemia cells to <scp>ABL</scp> tyrosine kinase inhibitors
|Cancer Science|2013|60
Expression of p‐JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia
|International Journal of Cancer|2011|47
Analysis of Aurora B kinase in non-Hodgkin lymphoma
|Laboratory Investigation|2009|39
AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells
|Molecular Cancer Therapeutics|2010|29